Total Matrix Metalloproteinase-2 and Prostaglandin E2 as Potential Biomarkers in Iraqi AML Patients
DOI:
https://doi.org/10.37506/mlu.v21i1.2326Keywords:
AML, MMP-2,PGE2, ELISA, Matrix metalloproteinase, prostaglandin E2Abstract
Acute Myeloid Leukemias (AMLs) are rare but extremely malignant neoplasms that are liable for a big
amount of fatalities associated with cancer. Acute myeloid leukemia (AML) results from accumulation of
abnormal myeloblasts, most commonly in the bone marrow, leading to bone marrow failure and death. The
present study was carried out to evaluate MMP-2 and PG E2 in sera and of (50) AML Iraqi patients, In addition
to control group involving (50) matched apparently healthy subjects. This study was done in the National
center of hematology, Department of biology at AL-Mustansiyria University, Baghdad Medical City since
January 2019 to June 2020. The aim of study was to determine the level of total Matrix Metalloproteinase
2 and prostaglandin E2 in patients with AML by ELISA. and study the impact of these parameters on the
pathogenesis of disease, also predict the AML and how the parameters correlated with stages and severity
of disease and responsiveness to therapy. Conclusion: MMP-2 decreased and elevated of PGE2 in the serum
of AML patients .
